As kidney disease and heart disease are closely related (Zoccali et al., 2023; Sano, 2020), this drug, as an aldosterone receptor antagonist, can antagonize the mineralocorticoid receptor (MR) to reduce fibrosis of the heart and kidney caused by MR overactivation (Kolkhof et al., 2014; Agarwal et al., 2021; Grune et al., 2018). Here, NR3C2 is linked to kidney disorder.